Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:58:15.168Z.
Consensus retrieved: 2026-10-06T15:14:38.062Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:58:15.168Z.
Quote observation: 2026-10-06T18:55:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e72a758e634708c28c06ae15f1e09243225437df43ff658102191b35b06d910
FORWARD PE RATIO
N/A
Pharvaris N.V.
Market Cap
$2.16B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pharvaris N.V. (PHVS) | $2.16B | N/A |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | N/A |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.13B | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.21B | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 16.03 |
| Vera Therapeutics, Inc. (VERA)vs › | $2.09B | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | N/A |
| Vericel Corporation (VCEL)vs › | $2.07B | 75.59 |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.07B | N/A |
| Alvotech (ALVO)vs › | $2.07B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in EUR, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
